Pliant Therapeutics (PLRX) Non-Current Deffered Revenue (2019 - 2020)
Pliant Therapeutics (PLRX) reported Non-Current Deffered Revenue of $581000.0 for Q4 2020, up 26.86% year-over-year from $458000.0 in Q1 2020, and up 2.83% quarter-over-quarter from $565000.0 in Q3 2020.
Pliant Therapeutics (PLRX) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has 2 years of Non-Current Deffered Revenue data on file, last reported at $581000.0 in Q4 2020.
- Non-Current Deffered Revenue for Q4 2020 came in at $581000.0, up 26.86% year-over-year; the trailing twelve-month figure through Dec 2020 was $581000.0 (up 26.86% YoY), and the FY2020 annual result was $581000.0, up 26.86% from the prior year.
- Non-Current Deffered Revenue improved to $581000.0 in Q4 2020 per PLRX's latest filing, from $565000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $581000.0 in Q4 2020 and troughed at $458000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 581,000.00 |
| Sep 30, 2020 | 565,000.00 |
| Jun 30, 2020 | 540,000.00 |
| Dec 31, 2019 | 458,000.00 |